ASCO GU 2022: TROPHY-U-01 Suggests Promise for Second-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Carcinoma
The combination of antibody-drug conjugates and immune checkpoint inhibitors should be studied further
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.